Short Course Radiation for Stage 1 Lung Cancer better than conventional radiation

A study from Australia published in Lancet Oncology this month shows: In patients with inoperable peripherally located stage 1 NSCLC, compared with standard radiotherapy, SABR (SBRT) resulted in superior local control of the primary disease without an increase in major toxicity. The findings of this trial suggest that SABR (SBRT) should be the treatment of choice for this patient group

Short Course Radiation for Lung Cancer

SBRT for Renal Cancer in patients with one kidney

High-dose, high-precision radiation therapy safe and effective for kidney cancer patients with only one kidney

Treatment of renal cell carcinoma with SABR is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. SABR has been shown to be effective in treating cancers in the lung, liver and spine using substantially
higher doses of radiation delivered in a single, or just a few, treatment sessions. The abstract was presented at ASTRO 2018 by lead author Rohann J. M. Correa, MD, PhD, with London Health Sciences Center in London, Canada

More support for short course radiation for prostate

ASTRO 2018: John Staffurth, MD, MB, from Cardiff University, gave an update on the progress of the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) trial. The five-year findings of this noninferiority trial show evidence that hypofractionation (60 Gray in 20 fractions or 57 Gray in 19 fractions) reduces long-term sexual side effects with no significant effect on bowel or urinary side effects in patients with localized prostate cancer versus a traditional treatment schedule (74 Gray in 37 fractions).


Short Course Radiation for Breast Cancer Study

Long-term side effects similarly low for once-weekly and conventional breast radiation therapies, trial finds

ASTRO 2018 Annual Meeting: In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer, larger individual doses experienced similarly low rates of late-onset side effects as those undergoing conventional radiation therapy. The abstract, FAST phase III RCT of radiation therapy hypofractionation for treatment of early breast cancer: 10-year results (CRUKE/04/015), was presented by lead author Murray Brunt, MD, a professor of clinical oncology at University Hospitals of North Midlands and Keele University in the United Kingdom (UK), and lead author of this study. The trial was designed to assess changes in healthy breast tissue following conventional radiation treatment compared with two shorter regimens that delivered higher doses of radiation in fewer sessions.

Dr. Vijay Kini specializes in the treatment of cancer using radiation technology and therapies. We are located at 2895 Edinger Avenue, Tustin, CA 92780. We are open from: 8:00 AM to 5:00 PM PST Monday through Friday. Reach out to us at 949-381-5800 for help.

Copyright © 2022 Practice Builders and Dr Vijay Kini, MD. All rights reserved.